Advanced search

The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.

Download
[thumbnail of Spalton et al JTH 2009.pdf]
Text
· Restricted to Repository staff only
· The Copyright of this document has not been checked yet. This may affect its availability.
Restricted to Repository staff only
Advice

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Tools
Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email
Lists

Spalton, J. C., Mori, J., Pollitt, A. Y. orcid id iconORCID: https://orcid.org/0000-0001-8706-5154, Hughes, C. E. orcid id iconORCID: https://orcid.org/0000-0002-9790-5820, Eble, J. A. and Watson, S. P. (2009) The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. Journal of thrombosis and haemostasis : JTH, 7 (7). pp. 1192-9. ISSN 1538-7836

Abstract/Summary

The inhibitory effect of R406 provides direct evidence of a role for Syk in GPVI, CLEC-2 and integrin alphaIIbbeta3 signaling in human platelets. Further, the results demonstrate a critical role for Syk in mediating tyrosine phosphorylation of CLEC-2, suggesting a novel model in which both Src and Syk kinases regulate tyrosine phosphorylation of the C-type lectin receptor leading to platelet activation.

Item Type Article
URI https://reading-clone.eprints-hosting.org/id/eprint/44578
Refereed Yes
Divisions Life Sciences > School of Biological Sciences > Biomedical Sciences
Download/View statistics View download statistics for this item
Deposit Details

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar